Factors associated with virological response in women receiving highly-active antiretroviral prophylaxis for HIV-1 mother-to-child transmission;Factores asociados a respuesta virológica en mujeres que usaron profilaxis antirretroviral de gran actividad para transmisión materno-fetal del virus de la inmunodeficiencia humana tipo 1

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue 7, 2008, Pages 411-415

  Palacios, Ricardo ^a   Senise, Jorge F ^a   Vaz, Maria José R ^a   Castelo, Adauto ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antiretrovirals; HIV 1; Mother to child transmission; Pregnancy; Prophylaxis; Viral load

Indexed keywords

LOPINAVIR; NELFINAVIR; RITONAVIR;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; VERTICAL TRANSMISSION; VIRUS LOAD;

EID: 52249091540     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13125637     Document Type: Article

References (13)

1. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Díaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-94.
2. Hawkins D, Blott M, Clayden P, de Ruiter A, Foster G, Gilling-Smith C, et al. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission of HIV. HIV Med. 2005;6 Suppl 2:107-48.
3. Iribarren JA, Labarga P, Rubio R, Berenguer J, Miró JM, Antela A, et al. Recomendaciones de GESIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en pacientes adultos infectados por el Virus de la Inmunodeficiencia Humana (Diciembre 2005). Grupo de Estudio de Sida (GESIDA) y Consejo Asesor Clínico (CAC) del Plan Nacional sobre el SIDA (PNS) del Ministerio de Sanidad y Consumo (MSC); 2005 [actualizado 2005; consultado 7 Feb 2006]. Disponible en: http://www.gesidaseimc.com/documentos/pdf/Recomendaciones- TAR-GESIDA-PNS.pdf
4. Ministério da Saúde do Brasil, Secretaria de Vigilância em Saúde. Recomendações para profilaxia da transmissão vertical do HIV e terapia anti-retroviral em gestantes. Brasília: Ministério da Saúde do Brasil; 2007.
5. Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1 Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States; 2006 [citado 2007]. Disponible en: http://aidsinfo.nih.gov/ ContentFiles/PerinatalGL.pdf
6. Senise JF, Palacios R, Tanno ZN, Lunardi L, Waghabi GR, Vaz MJ, et al. HIV-1 viremia during the first 28 weeks of pregnancy is not associated with mother-to-child transmission. Braz J Infect Dis. 2006;10:259-63.
7. Timmermans S, Tempelman C, Godfried MH, Nellen J, Dieleman J, Sprenger H, et al. Nelfinavir and nevirapine side effects during pregnancy. Aids. 2005;19:795-9.
8. Madec Y, Boufassa F, Porter K, Meyer L. Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. Aids. 2005;19:2001-7.
9. Ioannidis JP, Abrams EJ, Ammann A, Bulterys M, Goedert JJ, Gray L, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads < 1000 copies/ml. J Infect Dis. 2001;183:539-45.
10. Morris AB, Dobles AR, Cu-Uvin S, Zorrilla C, Anderson J, Harwell JI, et al. Protease inhibitor use in 233 pregnancies. J Acquir Immune Defic Syndr. 2005;40:30-3.
11. Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Pérez P, Pérez JL, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther. 2002;7:81-90.
12. King MS, Bernstein BM, Walmsley SL, Sherer R, Feinberg J, Sanne I, et al. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis. 2004;190:280-4.
13. Gathe JC, Jr., Ive P, Wood R, Schurmann D, Bellos NC, DeJesus E, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. Aids. 2004;18:1529-37.